Anti-HPV-16 E2, Polyclonal
Invented by Dr Lawrence Banks from International Centre For Genetic Engineering And Biotechnology (ICGEB)
Invented at International Centre For Genetic Engineering And Biotechnology (ICGEB)
- Datasheet
- References (2)
- Inventor Info
Info
| Catalogue Number | 153962 |
| Applications | IF IP WB |
| Antigen/Gene or Protein Targets | HPV-16 E2 |
| Synonyms | Human papillomavirus type 16 E2 protein |
| Reactivity | Human papilloma virus |
| Relevance | Nearly all cases of cervical cancer are associated with HPV infection, with two types, HPV16 and HPV18, present in 70% of cases. HPV type 16 is the most malignant strain, present in 41 to 54% of all cervical cancers, and in many cases of vaginal/vulvar cancer, penile cancers, anal cancers, and cancers of the head and neck. In 2012, about 528,000 new cases and 266,000 deaths from cervical cancer occurred worldwide. HPV viral genes E6 and E7 acts as oncogenes to promote tumour formation and malignant transformation. The E2 proteins are pivotal to the viral life cycle and have well characterized functions in transcriptional regulation, initiation of DNA replication and partitioning the viral genome. All E2 proteins are sequence specific DNA binding proteins that bind to 12bp motifs located mostly within the Upstream Regulatory Region (URR) of the viral genomes. |
| Host | Rabbit |
| Immunogen | Recombinant HPV-16 E2 |
| Formulation | Serum |
| Molecular Weight (kDa) | 43kDa |
| Notes |
WB 1:1000 IF 1:1000 |
| Research Area | Cancer, Virology |
References: 2 entries
Johansson et al. 2012. EMBO J. 31(14):3212-27. PMID: 22617423.
HPV-16 E2 contributes to induction of HPV-16 late gene expression by inhibiting early polyadenylation.
Europe PMC ID: 22617423
Add a reference
References: 2 entries
Johansson et al. 2012. EMBO J. 31(14):3212-27. PMID: 22617423.
HPV-16 E2 contributes to induction of HPV-16 late gene expression by inhibiting early polyadenylation.
Add a reference
